ARABIAN-CHEMICAL
15.5.2024 20:34:30 CEST | Business Wire | Press release
Arabian Chemical Terminals LLC in Abu Dhabi (ACTAD) is proud to announce the start of operations at its newly built chemical tank storage terminal in Khalifa Port, Abu Dhabi, UAE. The terminal is the first commercial chemical tank farm of its kind in the Emirate.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515922771/en/
ACT Abu Dhabi open for business (Photo: AETOSWire)
Strategically located in the new world class Khalifa Port and adjacent to the modern and sprawling Khalifa Economic Zone Abu Dhabi (KEZAD), ACTAD aims to participate in the drive to promote new industries in the Emirate.
ACTAD was designed and built as State of the Art in compliance with the highest international standards and boasts a total of 40 tanks of various specifications (20 Carbon Steel including 10 with IFR and 20 Stainless Steel including 10 insulated with heating/cooling system) for a total of 100,000 CBM storage capacity. Each tank has a devoted pipeline to a dedicated berth of 16 meters draft and dedicated truck loading bays, therefore, eliminating the risks of cross product contamination, promoting maximum operating efficiency and flexibility to the customers.
Additionally, the site has a 500 sqm warehouse for dangerous goods and provision for drums/IBCs filling.
The terminal has an independently operated third party fully equipped surveyor laboratory for sampling and testing.
ACTAD operates with an Integrated Management System following International Standards; ISO-9000, 14000, 18000, CDI-T and ISGOTT.
The Terminal will help local industries to import their liquid chemical needs in bulk or export their liquid chemical products to the globe. It can also act as a storage hub and/or break-bulk operations for international companies as it is strategically located in a bonded zone within Khalifa Port.
ACTAD is an extension of Arabian Chemical Terminals LTD in Saudi Arabia (ACT-KSA). ACT-KSA is an owner/operator of two other terminals, one in Yanbu on the Red Sea coast and one in Jubail Commercial Port on the Arabian Gulf. From its humble beginnings in 1986 in Yanbu, ACT-KSA was the first commercial tank farm established in Saudi Arabia, starting with 13,000 CBM of storage capacity. In 2012 ACT-KSA built the first commercial bulk storage facility in Jubail adding a further 70,000 CBM of storage capacity with tanks varying in specifications and in sizes. The Jubail terminal is currently under expansion to add a further 70,000 CBM of capacity.
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515922771/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom